Home
>
US Stocks
>
Intellia Therapeutics Inc
Intellia Therapeutics Inc
NTLA

Intellia Therapeutics Inc (NTLA)

$131.614.81%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
133.79
Today Low/High
129.52 / 133.79
52 Week Low/High
$16.54 / $202.73
P/E ratio
-60.9404
Market Cap
$11.28B

Company Details

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.
Organisation
Intellia Therapeutics Inc
Headquaters
Cambridge, Massachusetts, US
Employees
312
Industry
Health Technology
CEO
John Leonard

Discover more

Frequently Asked Questions

What is Intellia Therapeutics Inc (NTLA) share price today?

Can Indians buy Intellia Therapeutics Inc (NTLA) shares?

How can I buy Intellia Therapeutics Inc (NTLA) shares from India?

Can Fractional shares of Intellia Therapeutics Inc (NTLA) be purchased?

What are the documents required to start investing in Intellia Therapeutics Inc (NTLA) stocks?

We are a SEBI registered investement advisor